TNP-2092
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- TNP-2092
- DrugBank Accession Number
- DB16312
- Background
TNP-2092 is under investigation in clinical trial NCT03964493 (TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 1205.388
Monoisotopic: 1204.574394095 - Chemical Formula
- C65H81FN6O15
- Synonyms
- Not Available
- External IDs
- CBR-2092
- TNP-2092
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- W2P7EF7O6O
- CAS number
- 922717-97-3
- InChI Key
- OPZFMLLAJBIKAN-JNEXSVMGSA-N
- InChI
- InChI=1S/C65H81FN6O15/c1-31-13-12-14-32(2)61(80)68-50-44(56(77)47-48(57(50)78)55(76)37(7)59-49(47)60(79)64(9,87-59)85-26-20-46(84-11)33(3)58(86-38(8)73)36(6)54(75)35(5)53(31)74)28-67-71-24-18-41(19-25-71)69(10)65(21-22-65)40-17-23-70(29-40)52-34(4)51-42(39-15-16-39)27-43(63(82)83)62(81)72(51)30-45(52)66/h12-14,20,26-28,30-31,33,35-36,39-41,46,53-54,58,74-78H,15-19,21-25,29H2,1-11H3,(H,68,80)(H,82,83)/b13-12-,26-20-,32-14?,67-28+/t31-,33-,35+,36-,40+,46-,53-,54+,58+,64-/m0/s1
- IUPAC Name
- 8-[(3R)-3-[1-({1-[(E)-{[(7S,9E,11S,12S,13S,14S,15R,16R,17S,18S,19E)-13-(acetyloxy)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-26-yl]methylidene}amino]piperidin-4-yl}(methyl)amino)cyclopropyl]pyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid
- SMILES
- CO[C@H]1C=CO[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=C\C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@H](C)[C@H](OC(C)=O)[C@H]1C)C(\C=N\N1CCC(CC1)N(C)C1(CC1)[C@@H]1CCN(C1)C1=C(C)C3=C(C=C(C(O)=O)C(=O)N3C=C1F)C1CC1)=C2O
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Gram Positive Bacterial Infections / Skin and Subcutaneous Tissue Bacterial Infections 1 1 Completed Other Healthy Volunteers (HV) 1 1 Completed Other Prosthetic Joint Infections 1 1 Completed Treatment Acute Bacterial Skin and Skin Structure Infection (ABSSSI) / Prosthetic Joints Infection (PJI) 1 1 Completed Treatment Helicobacter Pylori Infection 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0134 mg/mL ALOGPS logP 5.52 ALOGPS logP 2.38 Chemaxon logS -5 ALOGPS pKa (Strongest Acidic) 3.63 Chemaxon pKa (Strongest Basic) 10.46 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 18 Chemaxon Hydrogen Donor Count 7 Chemaxon Polar Surface Area 281 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 330.61 m3·mol-1 Chemaxon Polarizability 126.49 Å3 Chemaxon Number of Rings 10 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 15, 2020 20:02 / Updated at September 12, 2023 18:32